1. Author's Information
    Monika
    University Institute of Pharmaceutical Sciences, Department of Pharmaceutical Chemistry Panjab University, Chandigarh, India

    Richa Dhingra
    University Institute of Pharmaceutical Sciences, Department of Pharmaceutical Chemistry Panjab University, Chandigarh, India

    Ankit Gupta
    University Institute of Pharmaceutical Sciences, Department of Pharmaceutical Chemistry Panjab University, Chandigarh, India

    Ashwani kaul
    Department of Biophysics, Panjab University, Chandigarh, India

    Manu Sharma
    Jay Pee University of Information Technology, Waknaghat, Solan, Himachal Pradesh, India

    Neelima Dhingra
    University Institute of Pharmaceutical Sciences, Department of Pharmaceutical Chemistry Panjab University, Chandigarh, India

  2. Abstract
    Traditional drug discovery methods have a basis in trial-and-error. In contrary, rational drug design approaches attempt to modulate specific structural features with the hope for a better therapeutic value. Typically, the quantitative structure activity relationship (QSAR) is one of the most widely used molecular modelling technique. Lantadenes are bioactive compounds derived from the Lantana camara showing anticancer potentials. But so far, no 2D and 3D-QSAR studies have been reported. Utilizing the advantage of this technique, in the present study, two and three-dimensional QSAR of lantadene derivatives have been developed for anticancer activity against A549 cell lines. The regression coefficient (r2), internal cross-validation regression coefficient (q2) and external crossvalidation regression coefficient (pred_r2) of derived QSAR models were 0.87, 0.81 and 0.82 respectively. Furthermore, in order to highlight the key structural controlling regions and different active and inactive sites, field points-based descriptors were used to develop a 3D-QSAR model by aligning known active compounds on to identified pharmacophore template. The derived LOO validated PLS regression QSAR model showed acceptable r2 0.81% and q2 0.78%. Hence, this method suggests the key structural features/ consideration in designing of lantadenes as potential anticancer agents.
    Keywords
    Lantadene, Anticancer, NF-kB, QSAR

    ADLID: 82507-v1
  3. Post New Comments

  1. Keywords
    Lantadene Anticancer NF-kB QSAR
Want to Index your journal in the ADL?
Suggest a Journal